Physician profile
Himanshu Wickramasinghe
NPI 1831118934
$3,581.53
in general payments reported to CMS, 2019-2025
22 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $283 · 2021: $280 · 2022: $506 · 2023: $339 · 2024: $734 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.57 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $795.72 | 2021-2025 | |
| Glaxosmithkline, LLC. | $537.17 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $513.41 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Insmed, INC. | $275.33 | 2021-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $265.94 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $167.33 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.34 | 2019-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $140.83 | 2024-2025 | |
| Advanced Respiratory, INC | $103.75 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $101.80 | 2024-2025 | |
| Philips North America LLC | $92.33 | 2022 | |
| Viatris Specialty LLC | $79.74 | 2025 | Yupelri |
| Amgen INC. | $65.64 | 2022-2025 | Tezspire |
| Lilly USA, LLC | $65.00 | 2025 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $63.12 | 2023-2024 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $30.65 | 2025 | |
| Mylan Specialty L.P. | $30.30 | 2019-2021 | |
| Pulmonx Corporation | $29.36 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.89 | 2024 | Nuzyra |
| Csl Behring | $19.86 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.52 | 2020 | |
| Circassia INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himanshu Wickramasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.